Forxiga’s CKD Indication Up for PAFSC Review on July 28, Possible OK in August

AstraZeneca’s SGLT2 inhibitor Forxiga (dapagliflozin) will come up for review by a key health ministry advisory committee on July 28 for an additional indication of chronic kidney disease (CKD). If it clears the panel, a typical schedule points to its...read more